Lonza– tag –
-
Biopharmaceuticals Contract Manufacturing Market Expands Amid Global Demand: CDMOs Scale Up Capacity
openPR.com Unknown Overview This article provides an overview of a market research report published by openPR.com. The biopharmaceutical contract manufacturing market is growing due to increased demand for biosimilars, expanded investmen... -
Lonza Achieves Strong H1 2026 Growth: CDMO Strategy Accelerates with Expanded ADC and High-Value Small Molecule Manufacturing
BioPharma BoardRoom Switzerland Overview Lonza CEO Wolfgang Wienand highlighted the company's strong growth in H1 2026, emphasizing the accelerating momentum of its CDMO strategy. Lonza expanded strategic long-term collaboration agreemen... -
Lonza and Engitix Ink ADC License Deal for ECM-Targeted Cancer, Fibrosis Therapies
GEN (Genetic Engineering & Biotechnology News) Switzerland Overview Lonza and Engitix Ltd. have signed a licensing agreement for an Antibody-Drug Conjugate (ADC) technology platform, targeting cancer and fibrosis therapies focused on the... -
FUJIFILM Cellular Dynamics Opens iPSC Manufacturing Facility, Made Scientific & Pluristyx Announce iPSC Partnership Expansion
openPR.com USA Overview According to openPR.com, FUJIFILM Cellular Dynamics opened a new iPSC development and manufacturing facility in Madison in May 2026, significantly expanding its induced pluripotent stem cell production capacity. F... -
Lonza Offers Integrated ADC Clinical and Commercial Manufacturing Services, Covering Antibody to Sterile Fill-Finish
Lonza Switzerland Overview Lonza offers integrated development and manufacturing services for Antibody-Drug Conjugates (ADCs), encompassing antibodies, payloads, bioconjugation, and sterile fill and finish. The company operates GMP produ... -
Lonza Expands Strategic Collaboration with Leading U.S. Biopharmaceutical Company, Adding Two Biologic Programs for Commercial Production and Enhancing Manufacturing with N-1 Perfusion Technology
Lonza Press Release Switzerland Overview Lonza has announced an expanded strategic collaboration with a leading U.S. biopharmaceutical company, adding two new biologic programs for commercial production. This multi-year agreement leverag... -
Lonza Accelerates DNA-to-IND Programs with New GS Ori‑Go™ Vector Technology: Delivers Tox Material in 2 Months, IND-Ready in as Fast as 6 Months
Lonza Press Release Switzerland Overview Lonza announced the enhancement of its preclinical development services, featuring the new GS Ori‑Go™ vector technology, to significantly accelerate DNA-to-IND (Investigational New Drug) programs.... -
Lonza Acquires Rights to Nona Biosciences’ TfR1 Blood-Brain Barrier Technology, Bolstering CNS Therapeutic Delivery Capabilities
Lonza Press Release Switzerland Overview Lonza has acquired the rights to Nona Biosciences' Transferrin Receptor 1 (TfR1) blood-brain barrier (BBB) technology, expanding its strategic collaboration with Nona. This acquisition aims to sig... -
Lonza Boosts Biologics Manufacturing with Dual Expansion: Swiss ADC Capacity and Enhanced US Biopharma Partnership with N-1 Perfusion Technology
Industry Week USA Overview Lonza has significantly strengthened its biopharmaceutical manufacturing capabilities through a massive expansion of its Antibody-Drug Conjugate (ADC) production capacity in Switzerland and an extended long-ter... -
Lonza’s OptiALTO™ Platform Achieves High Cell Density Culture, Significantly Reducing Biologics Manufacturing Costs
Lonza Switzerland Overview Lonza's OptiALTO™ platform enhances biologics manufacturing by enabling higher cell densities, which significantly reduces cost of goods by increasing productivity and efficient asset utilization. The platform ...
